Market Overview

JMP Securities Covers Mostly Good News From Pharma Pending More Visibility


Achillion Pharmaceuticals Inc.'s (NASDAQ: ACHN) recent interim data for its developmental hepatitis C drug is "incrementally positive," according to JMP Securities' Liisa A. Bayko.

Achillion's Monday data dump is among a half-dozen drug company developments that JMP analysts commented on Tuesday.

Bayko reiterated an Outperform rating and $24 price target on Achillion, but called it a "high risk" clinical plan by the company to use its NS5A inhibitor, ACH-3102, in combination with Gilead Sciences Inc.'s (NASDAQ: GILD) Sovaldi treatment for hepatitis C.

Boston Scientific Corp. (NYSE: BSX) agreement to market C.R. Bard Inc.'s (NYSE: BCR) drug-coated balloon called Lutonix in the U.S. got a thumbs up from JMP's J.T. Haresco.

Hareso reiterated an Outperform rating and $17 target on Boston Scientific, and said the Bard agreement covers part of Boston's strategy for selling a complete array of products aimed at peripheral arterial disease.

Horizon Pharma PLC (NASDAQ: HZNP) is making good with its $45 million October acquisition of the osteoarthritis drug Pennsaid, with sales of the product tracking toward $40 million in annual sales, JMP's Oren G. Livnat said.

Livnat raised his target on Horizon 11 percent to $20 and maintained an Outperform rating on the company, citing a possible earnings surprise Feb. 29.

Organovo Holdings Inc. (NYSE: ONVO) released its first product, 3D human liver tissue in the third quarter, but on Monday posted related revenue of only $155,000 for the period.

Hareso reiterated a Market Perform rating and said he'll wait for more "visibility" on liver revenue.

Pharmacyclics Inc. (NASDAQ: PCYC) released promising data on its Imbruvica drug from a Phase I lymphoma trial. The drug received marketing clearance for a fourth related indication last month.

JMP's Michael King reiterated an Outperform rating on Pharmacyclics along with a $253 target, predicting 2015 sales of $1.4 billion.

Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH) may benefit from proposed legislation enabling it to transfer to another company one year of market exclusivity on its eravacycline antibiotic candidate.

The proposal, a small piece of the so-called 21st Century Cures bill now before Congress, could make Tetraphase a more attractive buyout candidate, "or alternatively, it could create a source of financing" once eravacycline is approved, according to Bayko.

Bayko maintained an Outperform rating and $58 target on Tetraphase Tuesday.

Latest Ratings for ACHN

Oct 2019SVB LeerinkDowngradesOutperformMarket Perform
May 2019BarclaysDowngradesEqual-WeightUnderweight
May 2018BarclaysUpgradesUnderweightEqual-Weight

View More Analyst Ratings for ACHN
View the Latest Analyst Ratings


Related Articles (ACHN)

View Comments and Join the Discussion!

Posted-In: J.T. Haresco JMP Securities Michael King Oren G. LivnatAnalyst Color Analyst Ratings

Latest Ratings

CTASRBC CapitalMaintains360.0
MDTTruist SecuritiesMaintains120.0
ATEMaxim GroupInitiates Coverage On1.0
MNPRMaxim GroupInitiates Coverage On11.0
RDS/BScotiaBankInitiates Coverage On34.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at